Clinical Trial Update: Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of biweekly docetaxel in combination with capecitabine as first-line therapy for advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Taxotere (docetaxel)
• Xeloda (capecitabine)

Snippet

Sponsor: University of Turku | Conditions: Stomach Neoplasms | Phase 2 | Status: UNKNOWN